An observational study in Cancer, Gastrointestinal Cancer and Lung Cancer, sponsored by Oslo University Hospital. Completed. Open to male participants aged 40 Years to 49 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-01-25.
Sponsored by Oslo University Hospital · Observational
This study examines the effect of a five-year multifactorial lifestyle intervention in the Oslo diet and antismoking study on long-term cancer risk. In 1972-1973, 1232 men with high cardiovascular risk profile were randomised to intervention including cholesterol lowering diet, weight loss and antismoking advice, or control (1:1). This study examines the effect of the intervention on 43-year cancer incidence and mortality.
The Oslo diet and antismoking study showed that a 5-year lifestyle intervention reduced the long-term risk of coronary events and mortality. The lifestyle risk factors for cancer are partly similar to those for coronary heart disease, e.g. smoking, high body weight, unfavourable diet. The investigators therefore expect that the intervention has an effect on cancer risk in the long term.
In this follow-up study, the investigators analyse the association between the intervention, and cancer incidence and mortality drawn from the Cancer Registry of Norway and the Norwegian Cause of Death Registry from the time of randomisation in 1972/3 until the end of 2015.
10,818 studies on the registry are indexed under Neoplasms; 2,324 are open to participants now.
This study's enrollment of 1,216 is above the median of 200 across 2,638 observational studies indexed under Neoplasms.
Browse Neoplasms studies →Oslo University Hospital is the lead sponsor of 834 studies on the registry; 149 are open to participants now.
Counted across the registry records on this site, refreshed daily.
The participants selected for this follow-up study (n=1216) are the eligible subjects of the 1232 men at high cardiovascular risk profile who participated in the Oslo Diet and Antismoking Study (included in 1972-73). Fourteen men were excluded because they did not consent to studies other than the main study, and two more because of previous history of cancer.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Dietary and antismoking advice, aiming to reduce participant's risk of cardiovascular diseases
Behavioral: Diet and antismoking advice
No intervention
Dietary advice with the aim of reducing participant's serum cholesterol levels, including reduction in the intake of saturated fat and cholesterol, and increased intake of polyunsaturated fat, fish, vegetables and fruit. Weight reduction was recommended for overweight men, as well as reduced consumption of sugar rich foods and drinks, and alcoholic beverages. Smokers were advised to stop smoking. The advice was given both individually and in group sessions during a five-year time period from 1972/3 until 1977/8.
Incidence of the group of cancers related to smoking, diet or body mass index
Diagnosis of carcinoma in the oral cavity, oropharynx, esophagus, stomach, colorectum, liver and intrahepatic bile ducts, pancreas, larynx, trachea, bronchus and lung, urinary tract and thyroid gland, drawn from the Cancer Registry of Norway
Time frame: 43 years
Mortality in the group of cancers related to smoking, diet or body mass index
Mortality in cancers in the oral cavity, oropharynx, esophagus, stomach, colorectum, liver and intrahepatic bile ducts, pancreas, larynx, trachea, bronchus and lung, urinary tract and thyroid gland, drawn from the Norwegian Cause of Death Registry
Time frame: 43 years
Cancer incidence
Any cancer diagnosis, drawn from the Cancer Registry of Norway
Time frame: 43 years
Cancer mortality
Mortality in any cancer, drawn from the Norwegian Cause of Death Registry
Time frame: 43 years
Incidence of gastrointestinal cancer
Diagnosis of carcinoma in gastro-intestinal tract, drawn from the Cancer Registry of Norway
Time frame: 43 years
Incidence of lung cancer
Diagnosis of carcinoma in lung, drawn from the Cancer Registry of Norway
Time frame: 43 years
Incidence of urinary tract cancer
Diagnosis of carcinoma in urinary tract, drawn from the Cancer Registry of Norway
Time frame: 43 years
Incidence of prostate cancer
Diagnosis of carcinoma in prostate, drawn from the Cancer Registry of Norway
Time frame: 43 years
No study locations are listed for this record.
Plan to share: No
No publications or documents are linked to this record.
Ran from Jan 1972 to primary completion in Jun 2017, 545 months.
Of 1,098 non-industry observational studies under Neoplasms, half reached primary completion within 61 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 227. This study's 545 months is above that.
Counting every sponsor, half of 1,246 studies reached it within 58 months; a quarter within 24 and three quarters within 210.
Neoplasms covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.